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A Phase II Clinical Trial with Efficacy and
Toxicity Outcomes and Baseline Covariates
Kristian Brock, Lucinda Billingham, Christina Yap and Gary Middleton
Abstract PePS2 is a phase II trial of the efficacy and safety of pembrolizumab
in performance status 2 non-small-cell lung cancer patients. Previous studies have
shown that efficacy is correlated with the extent to which PD-L1 is expressed in the
tumour, and pretreatedness. There are few clinical trial designs that test co-primary
efficacy and toxicity outcomes in phase II, and fewer still that incorporate baseline
covariates. Thall, Nguyen and Estey present one such design but it has been scarcely
used in trials. Their model incorporates terms to conduct a dose-finding study. This
aspect is not required in PePS2 because a candidate dose has been widely tested. We
introduce a novel simplification for phase II that focuses on testing efficacy and tox-
icity whilst adjusting for baseline covariates. The method shares information across
cohorts. Simulations show it is far more efficient than analysing cohorts separately.
Using the design in PePS2 with 60 patients to test the treatment in six cohorts, we
can expect error rates typical of those used in phase II trials. However, we demon-
strate that care must be used when specifying the models for efficacy and toxicity
because more complex models require greater sample sizes for bias to be controlled.
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1 Introduction
There is a relative dearth of phase II clinical trial designs that incorporate patient
covariates to assess efficacy and toxicity. Thall et al.[10] introduced a family of
methods that perform dose-finding trials guided by binary efficacy and toxicity out-
comes whilst accounting for baseline patient covariates. This enables dose recom-
mendations tailored to individual patients. Our motivation is PePS2, a phase II trial
of pembrolizumab in non-small-cell lung cancer patients of performance status 2.
PePS2 is not a dose-finding trial. Instead, it seeks to estimate the probabilities of
efficacy and toxicity at a dose of pembrolizumab previously demonstrated to be safe
and effective in a closely-related group of patients[6]. In this piece, we implement a
simplification of Thall et al.’s method. We remove the dose-finding components but
retain aspects to study co-primary efficacy and toxicity outcomes that are associated
with baseline covariates.
2 The PePS2 Trial
PePS2 is a phase II trial of pembrolizumab in non-small-cell lung cancer (NSCLC)
patients with Eastern Cooperative Oncology Group (ECOG) performance status 2
(PS2). A patient with PS2 is ambulatory and capable of taking care of themselves
but typically too ill to work. Critically, it is doubtful that a PS2 patient could tolerate
the toxic side effects of chemotherapy.
The joint primary outcomes of the trial are (i) toxicity, defined as the occur-
rence of a treatment-related dose delay or treatment discontinuation due to adverse
event related to pembrolizumab; and (ii) efficacy, defined as the occurrence of sta-
ble disease (SD), partial response (PR) or complete response (CR) without prior
progressive disease (PD) at or after the second post-baseline disease assessment by
RECIST v1.1[5], scheduled to occur at week 18. The primary objective of the trial is
to learn if the treatment is associated with sufficient disease control with acceptably
low toxicity to use in performance status 2 patients.
Pembrolizumab inhibits the programmed cell death 1 (PD-1) receptor via the
programmed death-ligand 1 (PD-L1) protein. In a phase I study with 495 patients,
Garon et al.[6] showed pembrolizumab to be active and tolerable in performance
status 0 & 1 patients. Overall, 19.4% of patients had an objective response (PR
or CR) and 9.5% experienced an adverse event of grade 3 or higher. The rate of
toxicity compares favourably to those typically seen in advanced NSCLC patients
using chemotherapy [9, 1]. We foresee no reason why these outcome rates should
be materially dissimilar in PS2 patients.
Garon et al. introduce the PD-L1 proportion score biomarker, defined as the per-
centage of neoplastic cells with staining for membranous PD-L1. Efficacy outcomes
for the 204 patients in their validation group, allocated to cohorts based on PD-L1
score, are shown in Table 1. Objective responses are observed in all cohorts and the
rate of response increases with PD-L1 score.
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Table 1 Objective response rates for the validation sample (n = 204) of Garon et al.[6].
PD-L1 Cohort Criteria Objective Response %, (95% CI)
Low PD-L1 score < 1% 10.7 (2.3, 28.2)
Medium 1% ≥ PD-L1 score < 50% 16.5 (9.9, 25.1)
High PD-L1 score ≥ 50% 45.2 (33.5, 57.3)
Based on this information, we expect PD-L1 score to be predictive of response
in our PS2 population. Additionally, in the Garon trial 24.8% of treatment-naive
(TN) patients achieved a response, whereas only 18.0% did in the pre-treated (PT)
patients. Pretreatment status represents a potentially small but important effect that
should be considered when testing the treatment. We propose to investigate drug in
the six cohorts formed by jointly stratifying by the three Garon PD-L1 classifica-
tions; and the PT or TN statuses. Each patient in PePS2 will belong to exactly one
of these six cohorts, as demonstrated in Table 2.
Cohort Treatment status PD-L1 category xi = (x1i,x2i,x3i)
1 Treatment naive Low (0,1,0)
2 Treatment naive Medium (0,0,1)
3 Treatment naive High (0,0,0)
4 Pretreated Low (1,1,0)
5 Pretreated Medium (1,0,1)
6 Pretreated High (1,0,0)
Table 2 Cohorts used in the PePS2 trial. xi shows the predictive variable vector.
In phase II, there is strong motivation to deliver findings quickly to inform the
next study phase. Recruitment of approximately 60 PS2 patients within one year
would be feasible but accrual materially higher would be unlikely. Given the rel-
ative dearth of treatment alternatives, we seek to offer the trial to all PS2 patients
and not stratify accrual. Pembrolizumab has not been investigated in PS2 patients so
the clinical scenario requires a trial design that tests efficacy and toxicity. Given the
evidence that PD-L1 and pretreatedness are associated with response, it is highly
desirable to use a trial design that incorporates this predictive information. We de-
scribe our search for a clinical trial design that achieves these objectives.
3 Review of Available Experimental Designs
We sought trial designs that use explanatory variables to study joint primary out-
comes efficacy and toxicity. Using PubMed, we searched for publications under the
MeSH major topic ‘clinical trials’ that are categorised with the MeSH Terms ‘Drug-
Related Side Effects and Adverse Reactions’ and ‘Models, Statistical’.
Several manuscripts were identified detailing dose-finding designs that scrutinise
both efficacy and toxicity[2, 11, 12]. Each of these presents a model that could be
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adapted to our purpose. Very few phase II designs with co-primary outcomes were
identified. Bryant & Day[3] take threshold values for required rates of efficacy and
toxicity and return the threshold number of events to approve the treatment. For
given levels of significance and power, the threshold counts define the optimal trial
of competing efficacy and toxicity outcomes. The design implicitly assumes that the
patient population is homogeneous and does not use covariates. Parallel Bryant &
Day designs in our cohorts would require a prohibitively high sample size.
Finally, Thall, Nguyen & Estey (TNE)[10] introduce an extension of EffTox[11]
that adds baseline patient covariates to analyse co-primary efficacy and toxicity at
different doses. The objective of their Bayesian design is to recommend a personal
dose of an experimental agent, after adjusting for baseline covariates. Their de-
sign has enjoyed limited use. On 05-Dec-2017, we identified 16 manuscripts listed
on PubMed that cite Thall et al.[10], including 10 concerning further dose-finding
methodology. None sought to adapt the design to the typical phase II task of inves-
tigating efficacy and toxicity at a single dose. Five papers were reviews. Konopleva,
Thall et al.[8] use TNE in a dose-finding study of PR104 in relapsed or refractory
AML and acute lymphoblastic leukaemia (ALL). This literature search suggests
that TNE’s method has only been used in blood cancer and only for the purposes
of dose-finding. We found no suggestion that the method had been adapted for the
non-dose-finding context. We introduce a simplification of TNE for use in phase II.
4 Assessing efficacy and toxicity and adjusting for covariates
In this section, we describe novel adaptations to Thall et al.[10] to derive a model
that studies associated co-primary efficacy and toxicity outcomes, adjusted for base-
line covariates. We call this design P2TNE, for Phase II Thall, Nguyen & Estey.
Where prior information is available on outcomes under historic treatments,
Thall et al. present the general probability model
logitpik(τ,Z,θ) = β kZ +
m
∑
j=1
(µk, j +ξk, jZ)I(τ = τ j)+{gk(x,αk)+ γkZ}I(τ = x)
(1)
for k = E,T denoting efficacy and toxicity, respectively. Here, τ is the given dose; Z
is a vector of covariates; θ is the vector of model parameters to be estimated; β k is
the vector of main covariate effects; µk, j is a vector of historic main treatment effects
for m informative historic treatments; ξ k, j is vector of interactions between historic
treatment j and Z; I(A) is the indicator function, taking value 1 if A is true; gk(x,αk)
characterises the main dose effects; γk is a vector of dose-covariate interactions.
The authors introduce methods for associating the marginal efficacy and toxicity
models, and in their example reuse the Gumbel model deployed in EffTox[11]:
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pia,b(piE ,piT ) = (piE)a(1−piE)1−a(piT )b(1−piT )1−b
+(−1)a+b(piE)(1−piE)(piT )(1−piT )e
ψ −1
eψ +1
(2)
where ψ is an association parameter and a,b take the value 1 when efficacy and
toxicity occur respectively in a given patient, else 0.
We simplify this in P2TNE by removing dose-effect terms (g(.) = γ = 0) and
considering historic outcomes only for the treatment under investigation (m = 1).
Let xi denote the covariate data as specified in Table 2, and ai,bi the occurrence
of efficacy and toxicity in patient i. For trial data
X = {(x1,a1,b1), ...,(xn,an,bn)} (3)
the aggregate likelihood function is
L (X ,θ) =
n
∏
i=1
piai,bi(xi,θ) (4)
Let θ have prior distribution function f (θ). For patients with covariate data x, the
posterior expectation of the probability of efficacy under the treatment is
E(piE(x,θ)|X) =
∫
piE(x,θ) f (θ)L (X ,θ)dθ∫
f (θ)L (X ,θ)dθ
(5)
and the posterior probability that the rate of efficacy exceeds some threshold pi∗E is
Pr(piE(x,θ)> pi∗E |X) =
∫
I(piE(x,θ)> pi∗E) f (θ)L (X ,θ)dθ∫
f (θ)L (X ,θ)dθ
(6)
The treatment is acceptable in patients with covariates x if
Pr(piE(x,θ)> pi∗E |X)> pE
Pr(piT (x,θ)< pi∗T |X)> pT
(7)
where pi∗E , pE , pi∗T and pT are chosen by the trialists. Our lead clinician selected the
values pi∗E = 0.1 and pi∗T = 0.3 in all cohorts. We identified that pE = 0.7 and pT =
0.9 gave acceptable performance in indicative scenarios in our simulation study
described below. Our chosen models for marginal efficacy and toxicity are:
logitpiE(xi,θ) = α+βx1i + γx2i +ζx3i
logitpiT (xi,θ) = λ
(8)
, associated by (2). The four parameters in the efficacy model assume the log-odds
for PT patients in each PD-L1 category are a common linear shift of those in TN
patients, an assumption we call piecewise parallelism. Furthermore, the rate of toxi-
city is assumed uniform across groups, justified by data reported in Garon et al. and
Herbst et al.[7]. We analyse models that relax these assumptions.
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5 Simulation study
In a simulation study, we show that our model achieves error rates typical of phase II
clinical trials in all cohorts in indicative scenarios where efficacy and toxicity rates
are uniform across cohorts. Furthermore, we show that performance is very strong
in heterogeneous scenarios inspired by outcomes from Garon[6] and Herbst[7], far
surpassing that of beta-binomial conjugate analyses conducted in cohorts individu-
ally.
Choice of priors is contentious in clinical trials. We simulated performance under
diffuse, sceptical, and informative priors. Bias, inferred by coverage of posterior
credible intervals, was highest under the diffuse priors, suggesting benefit to using
priors that provide some central tendency that truly reflect investigators’ beliefs.
Our model choices (8) imply fairly strong assumptions. We analyse several
model embellishments to infer the cost in required sample size of greater model
freedom.
We relax the piecewise parallel assumption by adding interactions terms to the
efficacy model (8). Using this model in the scenarios described above, the probabil-
ity of approval decreases and bias increases. We find that 20 - 40 extra patients are
required to restore performance to that previously observed and eradicate bias.
Furthermore, we relax the assumption that toxicity is uniform over groups by
adding terms to the toxicity model. Again, the extra model freedoms without in-
creases in sample size yield lower approval probabilities and increased bias. Bias
is a particular problem in the toxicity model in scenarios when the expected event
rate is low. For instance, a four-parameter toxicity model suffers from material bias
estimating uniform 10% toxicity rates in all cohorts, particularly in the groups with
smallest expected size. This model is unbiased when the assumed true toxicity rate
is 30%. This is notable because the published data[6, 7] suggest low toxicity. This
model successfully identifies differential toxicity associated with covariates.
Lastly, simulations reveal that model performance is seemingly not affected by
efficacy and toxicity events being strongly associated. We investigated a model vari-
ant that assumes independent events by setting ψ = 0 in (2). The probability of
treatment approval was practically unchanged. This is perhaps not surprising when
we consider that ψ is not present in the marginal models for piE or piT . The associ-
ation parameter would aid inference if outcomes were partly observed so that, for
instance, the toxicity outcome is known but efficacy is unknown.
6 Further work and availability of materials
Statisticians are aware of the information loss that arises from dichotomising con-
tinuous variables. We use the PD-L1 categorisation published by Garon et al.[6]. In
ongoing work, we use the underlying continuous score.
Models are implemented in Stan[4] and all materials are available on GitHub at:
https://github.com/brockk/bebop
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